Quoin Pharmaceuticals Ltd. announced that the FDA granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare genetic skin disorder with no approved treatments. This designation facilitates development through more frequent FDA interactions, rolling review eligibility, and potential accelerated approval.
Key takeaways
FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome on March 11, 2026
QRX003 is being evaluated in two late-stage whole-body clinical trials for Netherton Syndrome
Previous designations: FDA Orphan Drug, Pediatric Rare Disease, and EMA Orphan Drug for QRX003
Netherton Syndrome is a rare genetic skin disorder caused by SPINK5 mutations with no FDA-approved therapies
Fast Track benefits include more frequent FDA interactions, rolling review, Accelerated Approval, and Priority Review eligibility